Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 135.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,201,226 shares of the company’s stock after acquiring an additional 691,267 shares during the period. Fisher Asset Management LLC owned about 1.26% of Viridian Therapeutics worth $25,922,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new position in Viridian Therapeutics during the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares in the last quarter. Bessemer Group Inc. boosted its position in shares of Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after buying an additional 1,886 shares during the period. US Bancorp DE grew its holdings in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares in the last quarter. Finally, Clearstead Advisors LLC grew its holdings in shares of Viridian Therapeutics by 3,868.3% during the third quarter. Clearstead Advisors LLC now owns 5,000 shares of the company’s stock valued at $108,000 after buying an additional 4,874 shares in the last quarter.

Viridian Therapeutics Trading Down 3.1%

Viridian Therapeutics stock opened at $29.32 on Wednesday. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $34.29. The company’s fifty day moving average price is $30.93 and its two-hundred day moving average price is $26.68. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -8.91 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. On average, analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VRDN. William Blair assumed coverage on Viridian Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Royal Bank Of Canada reduced their price target on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. UBS Group started coverage on shares of Viridian Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. Wells Fargo & Company boosted their target price on Viridian Therapeutics from $26.00 to $29.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $61.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, November 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $42.43.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.65% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.